| Company Name: |
BOC Sciences
|
| Tel: |
|
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:BMS 270394
CAS:262433-54-5
Purity:99% Remarks:BMS 270394 is a nuclear retinoic acid receptor (RAR-γ) agonist.
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:BMS270394;BMS270394
CAS:262433-54-5
Purity:98% Package:5 mg
|
| Company Name: |
Nanjing Tengyi Biotechnology Co., Ltd
|
| Tel: |
025-58851786 17714337195 |
| Email: |
sales@tybiochem.com |
| Products Intro: |
Product Name:Benzoic acid,3-fluoro-4-[[(2R)-hydroxy(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)acetyl]amino]-
CAS:262433-54-5
Purity:95+% Package:1g;5g
|
|
| | BENZOIC ACID, 3-FLUORO-4-[[(2R)-HYDROXY(5,6,7,8-TETRAHYDRO-5,5,8,8-TETRAMETHYL-2-NAPHTHALENYL)ACETYL]AMINO]- Basic information |
| Product Name: | BENZOIC ACID, 3-FLUORO-4-[[(2R)-HYDROXY(5,6,7,8-TETRAHYDRO-5,5,8,8-TETRAMETHYL-2-NAPHTHALENYL)ACETYL]AMINO]- | | Synonyms: | Benzoic acid, 3-fluoro-4-[[(2R)-2-hydroxy-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)acetyl]amino]- | | CAS: | 262433-54-5 | | MF: | C23H26FNO4 | | MW: | 399.46 | | EINECS: | | | Product Categories: | | | Mol File: | 262433-54-5.mol | ![BENZOIC ACID, 3-FLUORO-4-[[(2R)-HYDROXY(5,6,7,8-TETRAHYDRO-5,5,8,8-TETRAMETHYL-2-NAPHTHALENYL)ACETYL]AMINO]- Structure](CAS/GIF/262433-54-5.gif) |
| | BENZOIC ACID, 3-FLUORO-4-[[(2R)-HYDROXY(5,6,7,8-TETRAHYDRO-5,5,8,8-TETRAMETHYL-2-NAPHTHALENYL)ACETYL]AMINO]- Chemical Properties |
| storage temp. | -20°C | | solubility | DMSO: 20 mg/ml | | form | A solid |
| | BENZOIC ACID, 3-FLUORO-4-[[(2R)-HYDROXY(5,6,7,8-TETRAHYDRO-5,5,8,8-TETRAMETHYL-2-NAPHTHALENYL)ACETYL]AMINO]- Usage And Synthesis |
| Biological Activity | BMS 270394 is an agonist of retinoic acid receptor γ (RARγ; EC50 = 30 nM in a transactivation assay) and the active enantiomer of BMS 189961 .1 It is selective for RARγ over RARβ (EC50 = 400 nM) and is inactive at RARα. BMS 270394 synergizes with paclitaxel to inhibit the growth of MCF-7 breast and OVCAR-3 ovarian cancer, as well as SqCC/Y1 head and neck squamous cell carcinoma, cells.2 | | References | 1.Klaholz, B.P., Mitschler, A., Belema, M., et al.Enantiomer discrimination illustrated by high-resolution crystal structures of the human nuclear receptor hRARγProc. Natl. Acad. Sci. USA97(12)6322-6327(2000)
2.Vivat-Hannah, V., You, D., Rizzo, C., et al.Synergistic cytotoxicity exhibited by combination treatment of selective retinoid ligands with taxol (Paclitaxel)Cancer Res.61(24)8703-8711(2001) |
| | BENZOIC ACID, 3-FLUORO-4-[[(2R)-HYDROXY(5,6,7,8-TETRAHYDRO-5,5,8,8-TETRAMETHYL-2-NAPHTHALENYL)ACETYL]AMINO]- Preparation Products And Raw materials |
|